search
immunotherapy
Trends
- 1Immunotherapy startup Adecto shuts down, blaming funding climate▼Immmunotherapy startup Adecto blames ‘risk-adverse funding environment’ for closing down
Immunotherapy startup Adecto is closing down, with the company attributing its collapse to what it calls a risk-averse funding environment. The announcement underscores the continued pressure on early-stage biotech firms as investors pull back from unproven therapeutic platforms, leaving promising research pipelines without the capital needed to advance into clinical development.
- 2SITC Highlights Advances in Precision Immunotherapy and AI in Oncology▼Opportunity to Explore Advances in Precision Immunotherapy, Neoantigens, Spatial Biology and AI in IO - SITC
The Society for Immunotherapy of Cancer (SITC) is drawing attention to opportunities to explore recent advances in precision immunotherapy, including neoantigens, spatial biology, and the application of artificial intelligence in immuno-oncology. The announcement points to educational or conference programming where researchers and clinicians can examine how these fast-moving technologies are shaping cancer treatment.
- 3Michigan State Medical Society Hosts Medicine History and Cuba Cancer Event▼MSMS Hosts State of MSMS, History of Medicine, Cancer Immunotherapy from Cuba
The Michigan State Medical Society held an event combining its annual State of MSMS address with sessions on the history of medicine and cancer immunotherapy developments from Cuba. The programme highlighted Cuban research into lung cancer immunotherapy, an area where the country has developed its own vaccines and treatments and drawn international interest.
- 4Immunotherapy startup Adecto shuts down, blaming funding climate▼Immunotherapy startup Adecto blames ‘risk-averse funding environment’ for closing down
Adecto, an immunotherapy startup, has closed down and is attributing its collapse to what it calls a risk-averse funding environment. The company's closure adds to a string of biotech shutdowns as investors pull back from early-stage drug development, and it is drawing attention to how difficult conditions have become for clinical-stage startups seeking capital.
- 5AI Designs Working T-Cell Receptors for Immunotherapy Screening●AI Designs Working T-Cell Receptors That Could Transform Immunotherapy Screening
Researchers report that artificial intelligence has successfully designed functional T-cell receptors, a breakthrough that could speed up screening for immunotherapies. The AI-generated receptors are said to work in practice, suggesting machine learning can help engineer immune-cell treatments more quickly than traditional lab methods. The development is drawing attention for its potential to accelerate cancer immunotherapy research.